DRD2/DARPP-32 Expression Correlates with Lymph Node Metastasis and Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma

Overview

Journal World J Surg

Publisher Wiley

Specialty General Surgery

Date 2006 Jul 20

PMID 16850143

Citations 18

Authors

Li Li

Masaki Miyamoto

Yuma Ebihara

Seiji Mega

Ryo Takahashi

Ryunosuke Hase

Hiroyuki Kaneko

Masatoshi Kadoya

Tomoo Itoh

Toshiaki Shichinohe

Satoshi Hirano

Satoshi Kondo

Affiliations

Soon will be listed here.

Abstract

Background: Dopamine receptors (DRs) are members of seven transmembrane domain trimeric guanosine 5'-triphosphate (GTP)-binding protein-coupled receptor family. Through dopamine receptor activation, dopamine plays a significant role in regulating gene expression, such as induced tumor cell migration.

Materials And Methods: We investigated DRD1 and DRD2 expressions in patients with esophageal squamous cell carcinoma (ESCC) for immunohistochemistry and analyzed differences between DRD1, DRD2, and DARPP-32 expressions of clinicopathological features in 122 patients with ESCC.

Results: DRD1 immunostaining correlated with the pathologic grade (P = 0.0127), and DRD2 immunostaining correlated with the pathologic stage (P = 0.0432) and pN classification (P = 0.0112). A significant correlation was found between DRD1 and DRD2 expression (P = 0.0292). However, no correlation was observed between DRD1/DRD2 expression and DARPP-32 expression (P = 0.4555 and 0.4774, respectively). No correlation was observed between the DRD1/DRD2 expression and patient prognosis. To find the cooperative role between DRD1, DRD2, and DARPP-32 expressions, patients were classified into the different groups. In the DRD2/DARPP-32 combination, the (+/-) group was significantly correlated with pathologic stage (P = 0.0006), lymph node metastasis (P = 0.0001), pT (P = 0.0287), and tumor size (P = 0.0202). Moreover, patients with this combination showed a lower survival rate compared with the other three groups (P = 0.0287).

Conclusions: We conclude that DRD2/DARPP-32 expression is associated with tumor progression and that DRD2/DARPP-32 expressions may help predict prognosis in patients with ESCC.

Citing Articles

Research progress on the roles of dopamine and dopamine receptors in digestive system diseases.

Lu X, Liu Q, Deng Y, Wu J, Mu X, Yang X J Cell Mol Med. 2024; 28(7):e18154.

PMID: 38494840 PMC: 10945074. DOI: 10.1111/jcmm.18154.

Emerging Roles of the Nervous System in Gastrointestinal Cancer Development.

Wan C, Yan X, Hu B, Zhang X Cancers (Basel). 2022; 14(15).

PMID: 35954387 PMC: 9367305. DOI: 10.3390/cancers14153722.

Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cells.

Manoharan G, Okutachi S, Abankwa D PLoS One. 2022; 17(5):e0268635.

PMID: 35617282 PMC: 9135253. DOI: 10.1371/journal.pone.0268635.

Dopamine and dopamine receptor D1 as a novel favourable biomarker for hepatocellular carcinoma.

Wang Z, Wen P, Hu B, Cao S, Shi X, Guo W Cancer Cell Int. 2021; 21(1):586.

PMID: 34717619 PMC: 8557590. DOI: 10.1186/s12935-021-02298-9.

Exploring the Molecular Mechanism of Astragali Radix-Curcumae Rhizoma against Gastric Intraepithelial Neoplasia by Network Pharmacology and Molecular Docking.

Ji Y, Liu Y, Hu J, Cheng C, Xing J, Zhu L Evid Based Complement Alternat Med. 2021; 2021:8578615.

PMID: 34646329 PMC: 8505068. DOI: 10.1155/2021/8578615.

References

Boni R, Lichtensteiger W, Steinert H, Boni R, Fruh H, Dummer R . D1 dopamine receptors are not expressed in human melanoma. Melanoma Res. 1997; 7(2):117-9. DOI: 10.1097/00008390-199704000-00005. View

Saha B, Mondal A, Basu S, Dasgupta P . Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis. Int Immunopharmacol. 2001; 1(7):1363-74. DOI: 10.1016/s1567-5769(01)00068-6. View

Komukai S, Nishimaki T, Watanabe H, Ajioka Y, Suzuki T, Hatakeyama K . Significance of immunohistochemically demonstrated micrometastases to lymph nodes in esophageal cancer with histologically negative nodes. Surgery. 2000; 127(1):40-6. DOI: 10.1067/msy.2000.102754. View

Entschladen F, Lang K, Drell T, Joseph J, Zaenker K . Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother. 2002; 51(9):467-82. PMC: 11033027. DOI: 10.1007/s00262-002-0300-8. View

Hemmings Jr H, Greengard P, Tung H, Cohen P . DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. 1984; 310(5977):503-5. DOI: 10.1038/310503a0. View

Ebihara Y, Miyamoto M, Fukunaga A, Kato K, Shichinohe T, Kawarada Y . DARPP-32 expression arises after a phase of dysplasia in oesophageal squamous cell carcinoma. Br J Cancer. 2004; 91(1):119-23. PMC: 2364751. DOI: 10.1038/sj.bjc.6601899. View

Pivonello R, Ferone D, de Herder W, Kros J, De Caro M, Arvigo M . Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004; 89(5):2452-62. DOI: 10.1210/jc.2003-030837. View

Picardo M, Passi S, Breathnach A, Zompetta C, Faggioni A, Riley P . Mechanism of antitumoral activity of catechols in culture. Biochem Pharmacol. 1987; 36(4):417-25. DOI: 10.1016/0006-2952(87)90345-5. View

Montmayeur J, Bausero P, Amlaiky N, Maroteaux L, Hen R, Borrelli E . Differential expression of the mouse D2 dopamine receptor isoforms. FEBS Lett. 1991; 278(2):239-43. DOI: 10.1016/0014-5793(91)80125-m. View

10.

Greengard P, Allen P, Nairn A . Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron. 1999; 23(3):435-47. DOI: 10.1016/s0896-6273(00)80798-9. View

11.

Ishibashi M, Fujisawa M, Furue H, Maeda Y, Fukayama M, Yamaji T . Inhibition of growth of human small cell lung cancer by bromocriptine. Cancer Res. 1994; 54(13):3442-6. View

12.

Lang K, Drell 4th T, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker K . Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer. 2004; 112(2):231-8. DOI: 10.1002/ijc.20410. View

13.

Basu S, Dasgupta P . Alteration of dopamine D2 receptors in human malignant stomach tissue. Dig Dis Sci. 1997; 42(6):1260-4. DOI: 10.1023/a:1018862309440. View

14.

Basu S, Dasgupta P . Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue. Dig Dis Sci. 1999; 44(5):916-21. DOI: 10.1023/a:1026644110737. View

15.

Nishi A, Snyder G, Greengard P . Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci. 1997; 17(21):8147-55. PMC: 6573760. View

16.

Comings D, Gade-Andavolu R, Cone L, Muhleman D, MacMurray J . A multigene test for the risk of sporadic breast carcinoma. Cancer. 2003; 97(9):2160-70. DOI: 10.1002/cncr.11340. View

17.

Wick M . Levodopa/dopamine analogs as inhibitors of DNA synthesis in human melanoma cells. J Invest Dermatol. 1989; 92(5 Suppl):329S-331S. DOI: 10.1111/1523-1747.ep13076753. View

18.

Pivonello R, Ferone D, de Herder W, de Krijger R, Waaijers M, Mooij D . Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J Clin Endocrinol Metab. 2004; 89(9):4493-502. DOI: 10.1210/jc.2003-031746. View

19.

Yan Z, Feng J, Tomizawa K, Allen P, Fienberg A, Nairn A . Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nat Neurosci. 1999; 2(1):13-7. DOI: 10.1038/4516. View

20.

Scemama J, Ruellan C, Clerc P, Clemente F, Ribet A . Dopamine receptors in a human colonic cancer cell line (HT29). Some receptor-related biological effects of dopamine. Int J Cancer. 1984; 34(5):675-9. DOI: 10.1002/ijc.2910340515. View